An in vitro pharmacodynamic model was used to simulate the in vivo pharmacokinetics of clarithromycin and 14-hydroxyclarithromycin in order to generate time-kill curves for three clinical isolates of Haemophilus influenzae (isolates 2019, 91-183, and 1746). Representative 
influenzae (isolates 2019, 91-183, and 1746). Representative concentrations in serum or lung tissue and the pharmacokinetic parameters of clarithromycin and the 14-hydroxy metabolite, separately and in combination, were simulated for the time-kill studies. Amoxicillin-clavulanic acid was used as a control drug. The simulation of typical concentrations of the macrolides in serum in time-kill studies resulted in magnitudes of bacterial killing that were less than (for strains 2019 and 91-183, MICs = 4 mg/liter for clarithromycin and 14-hydroxyclarithromycin) or equal to (for strain 1746, MIC = 1 mg/liter for clarithromycin and 14-hydroxyclarithromycin) those observed in amoxicillin-clavulanic acid studies. When typical concentrations in lung tissue were simulated, total log decreases in bacterial counts were greater than those achieved with typical concentrations in serum and, in the case of strain 1746, exceeded the magnitude observed with the control drug. In each case, the time to 3-log-unit killing was longer for the macrolides than for amoxicillin-clavulanic acid. Time-kill curve analyses demonstrated the presence of synergy (defined as a 2-log-unit decrease in the CFU per milliliter between the combination and the most active constituent at any time point) for the combination of clarithromycin and 14-hydroxyclarithromycin at simulated concentrations in serum for one strain of H. influenzae (isolate 91-183). Synergism is likely bacterial strain specific, and the presence of synergy may be dependent on the antibiotic concentrations that are tested. Evaluation of the kdll curve kinetics in terms of bactericidal rate for the various starting concentrations of clarithromycin did not result in a clear demonstration of either concentration-dependent or concentration-independent bactericidal activity.
Erythromycin has been used clinically since 1952 and has well-established efficacy in the treatment of many respiratory and cutaneous infections. However, gastrointestinal intolerance of the drug and variable activity against Haemophilus influenzae limit the usefulness of erythromycin. Clarithromycin, a new macrolide antibiotic, has been shown to be well tolerated and effective in the treatment of acute and mild to moderate upper and lower respiratory tract infections, including those caused by H. influenzae (7, 8, 11, 13) . The active metabolite, 14-hydroxyclarithromycin, has been shown to inhibit strains of H. influenzae in an additive or synergistic fashion when tested in combination with the parent compound (4, 9, 12) . Additionally, pharmacokinetic studies have shown that clarithromycin and 14-hydroxyclarithromycin achieve high therapeutic concentrations in lung and other respiratory tract tissues (5) . As plates were incubated overnight at 37°C in a C02-enriched (5 to 10%) environment. The colonies on each plate were counted; the plated dilution that yielded a colony count of between 30 and 300 was used to construct the time-kill curves. Inoculation of a plate with 100 ,ul of undiluted sample resulted in a lower limit of bacterial quantitation of 3 x 102 CFU/ml.
MIC and MBC determinations. MICs and MBCs were determined by standard microtiter dilution techniques according to the current procedural recommendations of the National Committee for Clinical Laboratory Standards (10). Clarithromycin and 14-hydroxyclarithromycin were tested independently and in combination in a fixed 2:1 ratio. Analysis. Time-kill curve data were plotted as log CFU per milliliter versus time and were evaluated for total logarithmic decline and time to a 3-log-unit decline in bacterial numbers. Time-kill curves were also evaluated for the presence of a synergistic relationship between clarithromycin and the 14-hydroxy metabolite; synergy was defined as a 2-log1o-unit decrease in the number of CFU per milliliter for the combination in comparison with that for the most active constituent in the combination at any time point. Checkerboard MICs were evaluated for synergism on the basis of the sum of fractional inhibitory concentrations of clarithromycin and 14-hydroxyclarithromycin; a synergistic relationship was reported if the sum of the fractional inhibitory concentrations was less than 1 (2) . The kill curves generated at different initial clarithromycin concentrations were analyzed by linear regression between 1 and 6 h in order to evaluate the dependency of bacterial killing on concentration. 
RESULTS
Susceptibility testing. The MICs and MBCs of clarithromycin and 14-hydroxyclarithromycin for the study strains are given in Table 3 . The MICs were within the ranges that have previously been reported for H. influenzae (7) . Clarithromycin and 14-hydroxyclarithromycin were both bactericidal against all three strains of H. influenzae; MBCs were within 1 tube dilution of the MICs in all cases. No inoculum effect was noted; MICs and MBCs for high-inoculum (1 X 107 CFU/ml) tests were within 1 tube dilution of those for standard-inoculum (2 x 105 to 5 x 105 CFU/ml) tests.
Time-kill kinetic studies. Growth control curves performed for each bacterial strain demonstrated logarithmic growth to approximately 109 CFU/ml. The addition of the 0.1 M phosphate buffer to the medium did not affect the growth control curves.
Time-kill curves for clarithromycin, 14-hydroxyclarithromycin, and amoxicillin-clavulanic acid against H. influenzae 2019, 91-183, and 1746 are illustrated in Fig. 2, 3, and 4 , respectively. Results of the time-kill analyses are summarized in Table 4 .
Clarithromycin and 14-hydroxyclarithromycin produced consistent 3-log1o-unit declines in bacterial counts only for H.
influenzae 1746 (MIC, 1 mg/liter for both clarithromycin and 14-hydroxyclarithromycin). For the two bacterial strains for which the MICs were higher (4 mg/l for both clarithromycin and the metabolite), clarithromycin and the 14-hydroxy metabolite were not consistently bactericidal (i.e., did not produce a 3-log1o-unit decline in bacterial count). Amoxicillin-clavulanic acid produced rapid 3-log1o-unit declines in bacterial counts for all three strains of H. influenzae; regrowth occurred after 6 h. In all cases, amoxicillin-clavulanic acid produced a faster bactericidal rate than clarithromycin or the 14-hydroxy metabolite. Table 5 . Bactericidal rate (defined as the slope of the linear regression line of the portion of the kill curve between 1 and 6 h) was highly correlated with the initial clarithromycin concentrations that were greater than the MIC for H. influenzae 91-183 (R2 = 0.999). This relationship could not be demonstrated for the other Haemophilus strains.
DISCUSSION
Clarithromycin is a unique macrolide antibiotic in that it has a metabolite which has activity that is equal to or greater than that of the parent drug (7). The 14-hydroxy metabolite is of further interest because of the reported additive or synergistic relationships between the parent and the metabolite against H. influenzae (4, 9, 12). Synergism was noted by both time-kill and checkerboard MIC methods against one of the three H. influenzae strains tested in the present study. In the time-kill studies, the synergistic relationship of the drugs against this strain was present only for the simulated concentrations of clarithromycin and 14-hydroxyclarithromycin in serum. Simulation of higher concentrations in lung tissue resulted in time-kill curves that were almost identical for clarithromycin, (14) . At antibiotic concentrations that are many times the MIC for bacteria, concentration-dependent antibiotics display an increased rate and extent of bacterial killing in comparison with those at concentrations near the MIC. In contrast, concentration-independent antibiotics have similar rates and extents of bacterial killing at concentrations near the MIC and at concentrations many times the MIC. Macrolide antibiotics have not been firmly established as either concentration dependent or concentration independent. Clarithromycin did not clearly exhibit either behavior in the present study. In most cases, the slope of the kill curve became more negative as the initial concentrations of clarithromycin were increased; however, this trend was variable. It is likely that concentration-independent behavior represents a saturation of concentration-dependent processes. This property may be variable within the range of the attainable concentrations of clarithromycin in serum and tissue.
The simulated concentrations of clarithromycin in lung tissue compared more favorably with those of amoxicillin-clavulanic acid than the simulated concentrations in serum in terms of the extent of bacterial killing. Bacterial killing was more rapid for amoxicillin-clavulanic acid than for clarithromycin and 14-hydroxyclarithromycin; this is likely an intrinsic difference between these two classes of antibiotics that is related to the different mechanisms of action. Regrowth was dramatic in the amoxicillin-clavulanic acid studies; however, regrowth occurred after 6 h, when amoxicillin and clavulanic acid concentrations had dropped to less than 0.125 and 0.05 mg/liter, respectively. Amoxicillin-clavulanate is typically administered at least every 8 h, and the regrowth phase of the kill curve after this time cannot be considered clinically relevant.
The limitations of the present study include the short duration and the one-dose nature of the time-kill curves as well as the limited number of strains studied. In general, the time-kill curves generated in the present study demonstrate that many strains of H. influenzae might effectively be treated with clarithromycin if antibiotic and metabolite concentrations at the site of infection are adequate.
